Scientist II, Degrader Antibody Conjugate Characterization

Nurix•Brisbane, CA

6d•$140,000 - $161,000

About The Position

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. You will lead the development of innovative analytical workflows that support and accelerate Nurix's DAC platform, applying your expertise in ADC and/or DAC characterization to solve complex scientific challenges. This is an opportunity to shape analytical strategy for a novel therapeutic platform at the forefront of drug discovery and development. This is a laboratory role requiring assay design, method development, hands-on execution, and scientific communication to project and platform teams. You will design and execute analytical strategies for high-throughput DAC screening, establish quality criteria that drive conjugate advancement decisions, and partner closely with conjugation chemistry, biology, and bioanalytical teams from early screening through candidate selection.

Requirements

PhD with 4+ years of industry experience in biochemistry, analytical chemistry, or a related discipline
Expertise in ADC/DAC & antibody characterization from method development to data interpretation
Expertise with LCMS & HPLC methods for antibody and conjugate analysis, including DAR, SEC, peptide mapping, HIC, and other relevant industry leading methods
Direct experience characterizing ADCs in an industry setting with working knowledge of conjugation chemistry, DAR heterogeneity, and common quality attributes
Track record of independently designing experiments, developing analytical methods, troubleshooting assay and instrument performance, and managing priorities across multiple concurrent programs
Ability to synthesize complex analytical datasets into actionable scientific conclusions and influence project decisions through clear communication to cross-functional teams

Nice To Haves

Experience with native LCMS, positional isomer analysis, glycan analysis, CE-SDS for expanded conjugate or antibody characterization
Background in peptide mapping, biophysical binding assays, and thermal stability
Familiarity with developability assessment, forced degradation, or formulation-support analytics for biologics
Familiarity & experience with Agilent instrumentation & analytical software (MassHunter, Byos, or equivalent)

Responsibilities

Design, execute and own the DAC screening characterization platform including DAR, aggregation, protein quantitation, and define the QC thresholds to advance conjugates for a program
Present findings to project and platform teams; collaborate with conjugation chemistry, bioanalytical, and cell screening groups to align workflows, coordinate sample flow, and influence conjugate advancement decisions
Lead and conduct in-depth characterization of antibodies and advanced DACs including positional isomers, glycosylation analysis, peptide mapping, and stability
Integrate DAR, purity, hydrophobicity, and stability data into unified assessments with QC cutoffs that drive go/no-go decisions; identify structure-quality trends across antibody, linker, and payload variables